69 results
8-K
EX-10.2
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
is an oncology focused commercialisation and development company, which is wholly owned by the Charity (as defined below) and is responsible
8-K
EX-99.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
, and Provention Bio (acquired by Sanofi), where she was responsible for the design and execution of clinical development plans and trials for multiple
8-K
EX-99.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
will reduce its control over these activities but will not relieve Tenet of its responsibilities. For example, Tenet will remain responsible for ensuring … on these parties for execution of its clinical trials, and only control certain aspects of their activities. Nevertheless, Tenet is responsible for ensuring
8-K
EX-10.3
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
. ProBioGen alone shall be responsible for paying any and all taxes (other than withholding taxes required by applicable law to be paid by ValenzaBio … of the GlymaxX® Technology lies with ProBioGen, and ProBioGen shall be responsible for all associated costs.
13.3
Maintaining. There is no obligation
8-K
EX-10.1
ELYM
Eliem Therapeutics Inc
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
assume, become responsible for, and thereafter timely pay, perform and otherwise discharge, in accordance with their respective terms, only … or be responsible or liable for any Liabilities of Seller, including the following (collectively, the “Excluded Liabilities”), and the Excluded
8-K
EX-99.5
p0hhcph084xg
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
5oebtypg
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
EX-99.4
qmrycyoiir4yrj
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
EX-99.2
zntfsh5
27 Jun 24
Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 Million Private Placement
4:22pm
8-K
EX-10.1
xv3zuf8j3mjwb25d
12 Jun 24
Departure of Directors or Certain Officers
4:41pm
DEFM14A
wz8hu
4 Jun 24
Proxy related to merger
8:00am
PREM14A
xr8vx08 kntasj3
17 May 24
Preliminary proxy related to merger
4:36pm
10-K/A
ct1 k6t3k
29 Apr 24
Annual report (amended)
4:02pm
DEFA14A
mp6mm02 mmrq
11 Apr 24
Additional proxy soliciting materials
8:10am
8-K
EX-10.5
6fyf3afp438s7lytx
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-2.1
q8ytyvx 770v2w8ok5
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.1
dfu3gjq8g
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am
8-K
EX-10.2
b2sv7pu6j6zw89i6b
11 Apr 24
Eliem Therapeutics Announces Agreement to Acquire Tenet Medicines and Concurrent $120 Million Private Placement
8:01am